Comparative Pharmacology
Head-to-head clinical analysis: ATHENTIA NEXT versus OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATHENTIA NEXT versus OVRAL.
ATHENTIA NEXT vs OVRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that inhibits ovulation and alters cervical mucus, reducing sperm penetration. Ethinyl estradiol suppresses gonadotropin release, preventing follicular development.
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Not established. ATHENTIA NEXT is not a recognized pharmaceutical agent. Consult official prescribing information.
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; clinically relevant for once-daily dosing.
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Renal excretion of unchanged drug: 60-70%; fecal/biliary elimination: 20-30%; hepatic metabolism accounts for <10%.
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive